Zyprexa Adhera gets panel review
Executive Summary
The once-monthly injectable version of Lilly's Zyprexa (olanzapine) is scheduled to be reviewed by FDA's Psychopharmacologic Drugs Advisory Committee Feb. 6. The committee will discuss the occurrence of severe somnolence in some patients receiving the depot formulation of the atypical antipsychotic, which is under consideration for schizophrenia...